Company: CWAN
Filing Date: 2025-03-20
Form Type: 424B3
Source: 0001193125-25-058975
Chunk: 50

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-20
Form: 424B3
Chunk 50
---
 the anticipated Closing Date of the Transactions. These forward-looking statements are identified by words such as “will,” “expect,” “believe,” “anticipate,” “estimate,” “should,” “intend,” “plan,” “potential,” “predict,” “project,” “aim,” and similar words or phrases. These forward-looking statements are based on current expectations and beliefs of management and current market trends and conditions. These forward-looking statements involve risks and uncertainties that are outside Clearwater’s and Enfusion’s control and may cause actual results to differ materially from those contained in forward-looking statements. These risks and uncertainties include, among others, those set forth under “Risk Factors,” as well as risks and uncertainties relating to:

| • |     | the ability of the parties to consummate the Transactions in a timely manner or at all; |

| • |     | the satisfaction (or waiver) of conditions to Closing of the Transactions; |

| • |     | potential delays in consummating the Transactions; |

| • |     | the timing, receipt and terms and conditions of any required governmental and regulatory approvals of the            
 Transactions that could delay the consummation of the Transactions or cause the parties to abandon the Transactions; |

| • |     | the possibility that Enfusion Stockholders may not approve the Merger Agreement Proposal; |

| • |     | the ability of Enfusion or of Clearwater to timely and successfully achieve the anticipated benefits of the 
 Transactions;                                                                                               |

| • |     | the occurrence of any event, change or other circumstance or condition that could give rise to the termination of 
 the Merger Agreement;                                                                                             |

| • |     | Enfusion’s or Clearwater’s ability to implement its respective business strategy; |

| • |     | significant transaction costs associated with the Transactions; |

| • |     | the possibility that the Transactions may be more expensive to complete than anticipated, including as a result 
 of unexpected factors or events;                                                                                |

| • |     | potential litigation relating to the Transactions; |

| • |     | the risk that disruptions from the Transactions will harm Enfusion’s or Clearwater’s business, 
 including current plans and operations;                                                        |

| • |     | the ability of Enfusion or of Clearwater to retain and hire key personnel; |

| • |     | potential adverse reactions or changes to business relationships of Enfusion or of Clearwater resulting from the 
 announcement or completion of the proposed transaction;                                                          |

| • |     | legislative, regulatory and economic